Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$48.01 - $173.25
Previous CloseN/A
Volume185.86K
Average Volume (3M)2.93M
Market Cap
$5.99B
Enterprise Value$13.18B
Total Cash (Recent Filing)$557.23M
Total Debt (Recent Filing)$430.81M
Price to Earnings (P/E)25.9
Beta0.91
Next Earnings
May 06, 2025EPS Estimate
-3.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding97,032,074
10 Day Avg. Volume2,499,557
30 Day Avg. Volume2,928,463
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.78
Price to Cash Flow (P/CF)19.50
P/FCF Ratio21.30
Enterprise Value/Market Cap2.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.32
Enterprise Value/Ebitda43.10
Forecast
1Y Price Target
$148.25Price Target Upside145.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementThe completion of patient enrollment and dosing in the Phase 1b DISCOVERY study for SRP-9004 shows advancement in the company's clinical programs.
Market OpportunityELEVIDYS remains the best option for most young DMD patients, and the commercial opportunity is largely intact.
Regulatory ProgressThe confirmation of the accelerated approval path for '9003 and the expected data and BLA filing in 2H25 are seen as positive catalysts for the company.
Bears Say
Market PenetrationThe fatal adverse event occurred in a 16-year-old non-ambulatory patient, impacting the expected penetration of ELEVIDYS in non-ambulatory patients.
Safety ConcernsSRPT stock can recover if management can address investor questions following a recent patient death (acute liver failure).
Sales ProjectionsELEVIDYS revenues are expected to fall short, especially following a reported patient death from acute liver injury and related trial halts.
---
Ownership Overview
4.14% Insiders
29.80% Mutual Funds
0.74% Other Institutional Investors
45.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $48.01 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $5.99B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 10 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Feb 26, 2025. The company reported $1.5 earnings per share for the quarter, missing the consensus estimate of $1.883 by -$0.383.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -3.21.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,032,074 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.5 in its last earnings report, missing expectations of $1.883. Following the earnings report the stock price went down -3.556%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
---
Sarepta Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$148.25 (145.28% Upside)
$148.25 (145.28% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 357.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $248.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.29%
12-Months-Change
Fundamentals
Return on Equity
19.71%
Trailing 12-Months
Asset Growth
21.40%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
---
SRPT Company Deck
---
SRPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a highly positive performance with record-breaking revenue growth, successful ELEVIDYS launch, and strong guidance for 2025. Although there are challenges related to insurance and manufacturing, the overall outlook remains robust due to strategic advancements and pipeline progress.Read More>---
SRPT Stock 12 Month Forecast
Average Price Target
$148.25
▲(145.28% Upside)
Technical Analysis
Alkermes
―
Blueprint Medicines
―
Axsome Therapeutics
―
Revolution Medicines
―
Legend Biotech
―
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
29/45 ratings generated profit
1 Year Average Return
+10.53%
reiterated a buy rating 6 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 64.44% of your transactions generating a profit, with an average return of +10.53% per trade.
---